Vertex Pharmaceuticals Inc (VRTX: NASDAQ)
$109.885 20.215 | 22.54%
03/29/17 - 12:01 PM ET
Portfolios with VRTX
- Portfolio NameUser Type
- ProAdage Capital
- ContributorMonster Momentum Stocks To ...
- ContributorBreakout Stocks Of The Week...
- UserMike Fatah's Mega Stock Por...
- Contributor10 Companies That Prove Sto...
- ContributorRelative Strength Trades fo...
- ContributorEarnings Short Squeeze Play...
- ProD.E. Shaw
Latest VRTX Headlines from TheStreet
- Jim Cramer's 'Mad Money' Recap: These Retailers Will Survive the Amazon Express 11.30.15 | 08:11 pm
- Clinton Drug Plan Cuts Market Exclusivity, Sets Mandatory R&D Spending 09.22.15 | 07:09 am
- Biotech Stocks Recover From Early-Morning Flash Crash 08.24.15 | 12:08 pm
- 50 Stocks to Watch for Good Plays: Jim Cramer's Best Blogs 08.14.15 | 09:08 pm
- 3 Stocks Boosting The Drugs Industry Higher 08.04.15 | 01:08 pm
- 3 Drugs Stocks Pushing Industry Growth 07.30.15 | 01:07 pm
- Vertex Pharmaceuticals (VRTX) Earnings Report: Q2 2015 Conference Call Transcript 07.30.15 | 10:07 am
- Trade-Ideas: Vertex Pharmaceuticals (VRTX) Is Today's Post-Market Leader Stock 07.29.15 | 04:07 pm
- Vertex Pharmaceuticals (VRTX) Is Strong On High Volume Today 07.15.15 | 10:07 am
- Vertex Pharmaceuticals (VRTX) Is Today's Unusual Social Activity Stock 07.02.15 | 12:07 pm
Press Releases for VRTX
- Vertex Reports Second Quarter 2015 Financial Results - Business Wire 07.29.15 | 04:07 pm
- Vertex To Announce Second Quarter 2015 Financial Results On July 29 - Business Wire 07.14.15 | 09:07 am
- ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation - Business Wire 07.02.15 | 01:07 pm
- Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors - Business Wire 06.18.15 | 04:06 pm
- Vertex Announces Data Presentations At European Cystic Fibrosis Society (ECFS) Conference - Business Wire 06.11.15 | 09:06 am
- Vertex And Parion Sciences Establish Collaboration To Develop Epithelial Sodium Channel (ENaC) Inhibitors In Cystic Fibrosis And Other Pulmonary Diseases - Business Wire 06.04.15 | 04:06 pm
- Vertex To Present At The Goldman Sachs Healthcare Conference On June 11 - Business Wire 06.03.15 | 04:06 pm
- New England Journal Of Medicine Publishes Data From Two Phase 3 Studies Of ORKAMBITM (lumacaftor/ivacaftor) in People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation - Business Wire 05.17.15 | 01:05 pm
- Vertex To Present At The UBS Healthcare Conference On May 19 - Business Wire 05.13.15 | 04:05 pm
- Food And Drug Administration Advisory Panel Voted 12 To 1 To Recommend Approval Of ORKAMBI™ (lumacaftor/ivacaftor) To Treat People With Cystic Fibrosis Ages 12 And Older Who Have Two Copies Of The F508del Mutation - Business Wire 05.12.15 | 04:05 pm
Partner Headlines for VRTX
- Healthcare - Top 5 Gainers / Losers as of 11:00 am - SeekingAlpha 03.29.17 | 11:03 am
- Vertex Combo Data on Kalydeco+VX-661 Positive in Phase III - Zacks 03.29.17 | 10:03 am
- Premarket Gainers as of 9:05 am - SeekingAlpha 03.29.17 | 09:03 am
- Stifel ups Vertex target to $129 on 'very impressive' Phase 3 results - The Fly 03.29.17 | 08:03 am
- Vertex Pharma's tezacaftor/ivacaftor combo successful in two late-stage studies; shares ahead 17% premarket - SeekingAlpha 03.29.17 | 08:03 am
- Biotech Stock Roundup: Regeneron, Tesaro Drugs Approved, Vertex Scores Big in Study - Zacks 03.29.17 | 08:03 am
- Vertex price target raised to $108 from $100 at Credit Suisse - The Fly 03.29.17 | 07:03 am
- Jefferies recommends buying Vertex into today's rally - The Fly 03.29.17 | 07:03 am
- Vertex price target raised to $124 from $105 at Citi - The Fly 03.29.17 | 05:03 am
- Vertex upgraded to Outperform from Market Perform at BMO Capital - The Fly 03.29.17 | 05:03 am